Advertisement

Topics

Latest "Stoke Therapeutics" News Stories

15:37 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Stoke Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Stoke Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Stoke Therapeutics for you to read. Along with our medical data and news we also list Stoke Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Stoke Therapeutics Companies for you to search.

Showing "Stoke Therapeutics" News Articles 1–25 of 8,100+

Extremely Relevant

Biotechnology firm Stoke Therapeutics raises $90m financing

The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic The post Biotechnology firm Stoke Therapeutics raises $90m financing appeared first on Pharma Business review.


Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein ...

Stoke’s antisense oligonucleotide reduces seizures and increases survival in mouse models of Dravet Syndrome Read more...

With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO

Ed Kaye stepped aside from Sarepta Therapeutics (NASDAQ: SRPT) last year after leading the company through one of the most noteworthy and controversial drug approvals in recent memory, for the Duchenne muscular dystrophy drug eteplirsen (Exondys 51). But his hiatus from a publicly traded biotech could be short-lived. Kaye’s new startup, Bedford, MA-based Stoke Therapeutics, […]


Stoke Therapeutics Announces $90M Series B Financing to Advance Novel Oligonucleotide Medicines ⁦@StokeTx⁩ https://www.businesswire.com/news/home/20181023005249/en/Stoke-Therapeutics-Announces-90-Million-Series-Financing …

Stoke Therapeutics Announces $90M Series B Financing to Advance Novel Oligonucleotide Medicines ⁦ @StokeTx⁩ https://www.businesswire.com/news/home/20181023005249/en/Stoke-Therapeutics-Announces-90-Million-Series-Financing …

Relevant

Stoke Therapeutics to Present Research Supporting Advancement of Dravet Syndrome Program at Annual Meeting of the Oligonucleotide Therapeutics Society

Stoke Therapeutics, Inc. will present research at the upcoming annual meeting of the Oligonucleotide Therapeutics Society supporting its approach of leveraging antisense oligonucleotides to increase protein expression for the treatment of Dravet Syndrome and other monogenic diseases. Isabel Aznarez, Ph.D., Stoke’s co-founder and vice pres...

Stoke Therapeutics to Present New Data on Lead Program at American Epilepsy Society's 2018 Annual Meeting

Stoke Therapeutics and research collaborators from the University of Michigan will present new preclinical data supporting Stoke’s development of its antisense oligonucleotide technology to treat Dravet Syndrome at the annual meeting of the American Epilepsy Society in New Orleans. Lori Isom, Ph.D., Maurice H. Seevers professor and c...

Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference

Stoke Therapeutics will present on its pioneering work to develop the first gene-specific, disease-modifying therapies for genetic epilepsies at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week. Chief Executive Officer Ed Kaye, M.D., will share details on Stoke’s novel approach to upregulate

STAT Plus: After Sarepta, going after the genetic causes of epilepsies at Stoke

Ed Kaye, the former Sarepta Therapeutics CEO, talks about what he’s up to at his new startup.

Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines

Lead candidate to treat the genetic cause of Dravet Syndrome expected to reach clinic by 2020 Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. The financing round was led by RTW I...

Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide ...

Lead candidate to treat the genetic cause of Dravet Syndrome expected to reach clinic by 2020 Read more...

Stoke Therapeutics brings in $90mm through Series B round

Stoke Therapeutics Inc. (gene expression platform for severe genetic diseases) closed a $90mm Series B round led by RTW Inves...

Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors

Stoke Therapeutics, Inc., today announced that veteran biotech executive Arthur Tzianabos, Ph.D., who has extensive experience in the development and commercialization of rare disease treatments, will join the company’s board of directors. Dr. Tzianabos, the CEO and president of Homology Medicines, joins the board as Stoke is advancing to...

UK on verge of bed bug infestation. Here’s how to spot them – and how to get rid of them – Stoke-on-Trent Live

Stoke-on-Trent LiveUK on verge of bed bug infestation. Here's how to spot them - and how to get rid of themStoke-on-Trent LiveThey hide in the cracks and crevices of your bed and only come out at night - and now the UK is set to face an epidemic of bed bugs. The small insects can be difficult to see to the naked eye - but you will know if you have them in your bed as they ...Bed bug bites: Have yo...

Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy

Stoke’s antisense oligonucleotide reduces seizures and increases survival in mouse models of Dravet Syndrome Stoke Therapeutics and research collaborators from the University of Michigan today present data demonstrating the efficacy of Stoke’s proprietary antisense oligonucleotide (ASO) technology in treating Dravet Syndrome in mouse models....

Stoke prepares for IND, IPO with $90M series B

Stoke unveils Dravet data that supported $90M series B

Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations

Company also relocating to expanded R&D facilities at 45 Wiggins Ave. in Bedford, Mass. Stoke Therapeutics today announced the addition of two senior leaders who bring substantial experience guiding regulatory strategy and managing clinical development and operations. Shamim Ruff, previously Chief Regulatory Affairs Officer and SVP,...

New research expected to stoke development of tailored drugs for certain types of #Cancer, say scientists at @karolinskainst and @uppsalauni, and colleagues in the U.K. and U.S.: http://ow.ly/kLvs30nET28 

New research expected to stoke development of tailored drugs for certain types of #Cancer, say scientists at @karolinskainst and @uppsalauni, and colleagues in the U.K. and U.S.: http://ow.ly/kLvs30nET28 

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear ...

Has Program To Improve Readmission Rates For Medicare Beneficiaries Backfired?

Two new studies stoke skepticism over a program that penalizes hospitals when readmissions within 30 days exceeded national averages. While some worry the program hurts the very people it's meant to protect, other experts defend the measures.

Social media scheme boosts breast cancer screening uptake

An NHS project using social media has driven a 13% increase in first time attendances for breast screening in Stoke-on-Trent over four years.

Q4 Preview: How Will Bayer Survive Patent Cliff?

Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of...   

China - The Next Promised Land For Korean Biosimilars?

Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market...   

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO The post Roche’s Genentech agrees to buy Jecure Therapeutics appeared first on Pharmaceutical Business review.

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with...   


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks